Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G6ES
|
|||
| Former ID |
DIB000907
|
|||
| Drug Name |
TAK-218
|
|||
| Indication | Neurological disorder [ICD-11: 6B60] | Discontinued in Phase 2 | [1] | |
| Company |
TAP Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lipid peroxidation (LPO) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009120) | |||
| REF 2 | ESR study on the antioxidant activity of TAK-218 in biological model membranes. Chem Pharm Bull (Tokyo). 2000 Jun;48(6):784-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.